Shah Sujal
- SEC CIK
- 0001588861
No open-market purchases or sales filed in the past year.
Current role at each company
- TVRD Tvardi Therapeutics, Inc.Directoras of Jun 11, 2026
- CBAY CymaBay Therapeutics, Inc.Chief Executive Officeras of Mar 22, 2024
Open-market trades in the past year
Open-market purchases (P) and sales (S) filed in the last 365 days, not counting derivative securities or duplicate filings. Values leave out price outliers.
- Bought
- –
- 0 filings
- Sold
- –
- 0 filings
- Net
- –
- Bought minus sold
- Companies
- 0
- With open-market trades
Trades
Every Form 4 that lists Shah Sujal as a reporting owner, including filings made jointly with others, grouped by company. Each row adds up one type of transaction in one filing. Only open-market purchases (P) and sales (S) are shown by default.
CBAY CymaBay Therapeutics, Inc.
Chief Executive Officer4 trades
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Dec 11, 2023 (view filing) | Dec 11 | Same day | Shah SujalChief Executive Officer | SSale | −64.9K | $20.00 | −$1.30M | −27.5%171.3K after | 2 lots10b5-1 |
| Nov 14, 2023 (view filing) | Nov 13 | 1 day | Shah SujalChief Executive Officer | SSale | −64.9K | $15.89 | −$1.03M | −27.5%171.3K after | 2 lots10b5-1 |
| Oct 10, 2023 (view filing) | Oct 9 | 1 day | Shah SujalChief Executive Officer | SSale | −64.9K | $14.20 | −$921.0K | −27.5%171.3K after | 10b5-1 |
| Jun 7, 2022 (view filing) | Jun 6 | 1 day | Shah SujalChief Executive Officer | PPurchase | +51.3K | $1.95 | +$100.0K | +42.8%171.3K after |